#AstellasPharma

Astellas Pharma reached a settlement with Lupin and Zydus in the Myrbetriq® patent infringement lawsuit, receiving a total of USD 60 million in settlement payments and USD 150 million in upfront license fees.

Astellas Pharma announced that the combination therapy of PADCEV (Enfortumab Vedotin) and Pembrolizumab improved event-free survival and overall survival in cisplatin-eligible muscle-invasive bladder cancer in the Phase III EV-304 trial.